These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 24762071)

  • 41. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.
    Jones DE; Goldman MD
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1281-91. PubMed ID: 25148422
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
    Rovituso D; Heller S; Schroeter M; Kleinschnitz C; Kuerten S
    J Neuroimmunol; 2014 Jul; 272(1-2):86-90. PubMed ID: 24814390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
    Mori M
    Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
    Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
    Fox EJ; Wynn D; Coles AJ; Palmer J; Margolin DH;
    J Neurol Sci; 2016 Apr; 363():188-94. PubMed ID: 27000249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
    Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
    Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spotlight on alemtuzumab.
    Jones JL; Coles AJ
    Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
    J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancolitis a novel early complication of Alemtuzumab for MS treatment.
    Vijiaratnam N; Rath L; Xu SS; Skibina O
    Mult Scler Relat Disord; 2016 May; 7():83-4. PubMed ID: 27237765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.
    Wiendl H; Kieseier B
    Nat Rev Neurol; 2013 Mar; 9(3):125-6. PubMed ID: 23358486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
    Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
    Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
    Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
    Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
    Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
    Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.